Cargando…

Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial

INTRODUCTION: The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and it has become a major public health burden worldwide, including in Vietnam. A large body of preclinical and clinical studies supports the safety of mesenchymal stem/stromal cells (MSCs) in the trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Duc M, Nguyen, Kien T, Nguyen, Anh H, Nguyen, Bach N, Nguyen, Liem Thanh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126295/
https://www.ncbi.nlm.nih.gov/pubmed/33986057
http://dx.doi.org/10.1136/bmjopen-2020-045788
_version_ 1783693746119901184
author Hoang, Duc M
Nguyen, Kien T
Nguyen, Anh H
Nguyen, Bach N
Nguyen, Liem Thanh
author_facet Hoang, Duc M
Nguyen, Kien T
Nguyen, Anh H
Nguyen, Bach N
Nguyen, Liem Thanh
author_sort Hoang, Duc M
collection PubMed
description INTRODUCTION: The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and it has become a major public health burden worldwide, including in Vietnam. A large body of preclinical and clinical studies supports the safety of mesenchymal stem/stromal cells (MSCs) in the treatment of lung injury, including COPD. The aim of this trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in combination with standard COPD medication treatments in patients with moderate-to-severe COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 and Vietnam Ministry of Health’s guidelines. METHODS AND ANALYSIS: This matched case–control phase I/II trial is conducted at Vinmec Times City International Hospital, Hanoi, Vietnam between June 2020 and December 2021. In this study, 40 patients will be enrolled and assigned into two age-matched, gender-matched and COPD condition-matched groups, including a UC-MSC group and a control group. Both groups will receive standard COPD medication treatment based on the GOLD 2019 guidelines and the Vietnam Ministry of Health protocol. The UC-MSC group will receive two doses of thawed UC-MSC product with an intervention interval of 3 months. The primary outcome measures will include the incidence of prespecified administration-associated adverse events and serious adverse events. The efficacy will be evaluated based on the absolute changes in the number of admissions, arterial blood gas analysis, lung function and lung fibrosis via CT scan and chest X-ray. The clinical evaluation will be conducted at baseline and 3, 6 and 12 months postintervention. ETHICS AND DISSEMINATION: Ethical approval was secured from the Ethical Committee of Vinmec International Hospital (number:166/2019/QĐ-VMEC) and Vietnam Ministry of Health (number:2002/QĐ-BYT). The results will be reported to trial collaborators, publication in peer-reviewed academic journals. TRIAL REGISTRATION NUMBER: NCT04433104.
format Online
Article
Text
id pubmed-8126295
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81262952021-05-26 Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial Hoang, Duc M Nguyen, Kien T Nguyen, Anh H Nguyen, Bach N Nguyen, Liem Thanh BMJ Open Respiratory Medicine INTRODUCTION: The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and it has become a major public health burden worldwide, including in Vietnam. A large body of preclinical and clinical studies supports the safety of mesenchymal stem/stromal cells (MSCs) in the treatment of lung injury, including COPD. The aim of this trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in combination with standard COPD medication treatments in patients with moderate-to-severe COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 and Vietnam Ministry of Health’s guidelines. METHODS AND ANALYSIS: This matched case–control phase I/II trial is conducted at Vinmec Times City International Hospital, Hanoi, Vietnam between June 2020 and December 2021. In this study, 40 patients will be enrolled and assigned into two age-matched, gender-matched and COPD condition-matched groups, including a UC-MSC group and a control group. Both groups will receive standard COPD medication treatment based on the GOLD 2019 guidelines and the Vietnam Ministry of Health protocol. The UC-MSC group will receive two doses of thawed UC-MSC product with an intervention interval of 3 months. The primary outcome measures will include the incidence of prespecified administration-associated adverse events and serious adverse events. The efficacy will be evaluated based on the absolute changes in the number of admissions, arterial blood gas analysis, lung function and lung fibrosis via CT scan and chest X-ray. The clinical evaluation will be conducted at baseline and 3, 6 and 12 months postintervention. ETHICS AND DISSEMINATION: Ethical approval was secured from the Ethical Committee of Vinmec International Hospital (number:166/2019/QĐ-VMEC) and Vietnam Ministry of Health (number:2002/QĐ-BYT). The results will be reported to trial collaborators, publication in peer-reviewed academic journals. TRIAL REGISTRATION NUMBER: NCT04433104. BMJ Publishing Group 2021-05-13 /pmc/articles/PMC8126295/ /pubmed/33986057 http://dx.doi.org/10.1136/bmjopen-2020-045788 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Respiratory Medicine
Hoang, Duc M
Nguyen, Kien T
Nguyen, Anh H
Nguyen, Bach N
Nguyen, Liem Thanh
Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial
title Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial
title_full Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial
title_fullStr Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial
title_full_unstemmed Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial
title_short Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control, phase I/II trial
title_sort allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (copd): study protocol for a matched case–control, phase i/ii trial
topic Respiratory Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126295/
https://www.ncbi.nlm.nih.gov/pubmed/33986057
http://dx.doi.org/10.1136/bmjopen-2020-045788
work_keys_str_mv AT hoangducm allogeneichumanumbilicalcordderivedmesenchymalstemstromalcellsforchronicobstructivepulmonarydiseasecopdstudyprotocolforamatchedcasecontrolphaseiiitrial
AT nguyenkient allogeneichumanumbilicalcordderivedmesenchymalstemstromalcellsforchronicobstructivepulmonarydiseasecopdstudyprotocolforamatchedcasecontrolphaseiiitrial
AT nguyenanhh allogeneichumanumbilicalcordderivedmesenchymalstemstromalcellsforchronicobstructivepulmonarydiseasecopdstudyprotocolforamatchedcasecontrolphaseiiitrial
AT nguyenbachn allogeneichumanumbilicalcordderivedmesenchymalstemstromalcellsforchronicobstructivepulmonarydiseasecopdstudyprotocolforamatchedcasecontrolphaseiiitrial
AT nguyenliemthanh allogeneichumanumbilicalcordderivedmesenchymalstemstromalcellsforchronicobstructivepulmonarydiseasecopdstudyprotocolforamatchedcasecontrolphaseiiitrial